ES2131973T3 - Empleo de 2-amino-4-(4-fluorobencilamino)-1-etoxicarbonilaminobencenos para la profilaxis y el tratamiento de las secuelas de la disminucion aguda y cronica del riego sanguineo cerebral, asi como de afecciones neurodegenerativas. - Google Patents

Empleo de 2-amino-4-(4-fluorobencilamino)-1-etoxicarbonilaminobencenos para la profilaxis y el tratamiento de las secuelas de la disminucion aguda y cronica del riego sanguineo cerebral, asi como de afecciones neurodegenerativas.

Info

Publication number
ES2131973T3
ES2131973T3 ES96945354T ES96945354T ES2131973T3 ES 2131973 T3 ES2131973 T3 ES 2131973T3 ES 96945354 T ES96945354 T ES 96945354T ES 96945354 T ES96945354 T ES 96945354T ES 2131973 T3 ES2131973 T3 ES 2131973T3
Authority
ES
Spain
Prior art keywords
prophylaxis
treatment
neurodegenational
fluorobencilamino
etoxicarbonylaminobenzenes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96945354T
Other languages
English (en)
Inventor
Angelika Rostock
Christine Tober
Chris Rundfeldt
Reni Bartsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asta Medica GmbH
Original Assignee
Asta Medica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH filed Critical Asta Medica GmbH
Application granted granted Critical
Publication of ES2131973T3 publication Critical patent/ES2131973T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION TRATA DEL EMPLEO DE LA COMPOSICION (I) O DE SUS SALES FARMACEUTICAMENTE APROVECHABLES PARA LA PROFILAXIS Y EL TRATAMIENTO DE LAS SECUELAS DE LA FALTA AGUDA O CRONICA DE RIEGO SANGUINEO CEREBRAL NORMAL, EN ESPECIAL LA APOPLEJIA, Y PARA EL TRATAMIENTO DE DESORDENES NEURODEGENERATIVOS.
ES96945354T 1995-10-26 1996-10-15 Empleo de 2-amino-4-(4-fluorobencilamino)-1-etoxicarbonilaminobencenos para la profilaxis y el tratamiento de las secuelas de la disminucion aguda y cronica del riego sanguineo cerebral, asi como de afecciones neurodegenerativas. Expired - Lifetime ES2131973T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19539861A DE19539861A1 (de) 1995-10-26 1995-10-26 Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen

Publications (1)

Publication Number Publication Date
ES2131973T3 true ES2131973T3 (es) 1999-08-01

Family

ID=7775835

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96945354T Expired - Lifetime ES2131973T3 (es) 1995-10-26 1996-10-15 Empleo de 2-amino-4-(4-fluorobencilamino)-1-etoxicarbonilaminobencenos para la profilaxis y el tratamiento de las secuelas de la disminucion aguda y cronica del riego sanguineo cerebral, asi como de afecciones neurodegenerativas.

Country Status (26)

Country Link
US (2) US5852053A (es)
EP (1) EP0857065B1 (es)
JP (2) JP4567101B2 (es)
KR (1) KR100423823B1 (es)
AR (1) AR004108A1 (es)
AT (1) ATE178487T1 (es)
AU (1) AU706735B2 (es)
BR (1) BR9610899A (es)
CA (1) CA2188841C (es)
CZ (1) CZ291456B6 (es)
DE (2) DE19539861A1 (es)
DK (1) DK0857065T3 (es)
ES (1) ES2131973T3 (es)
GR (1) GR3030336T3 (es)
HU (1) HU228014B1 (es)
ID (1) ID16489A (es)
IL (1) IL123523A (es)
NO (1) NO316493B1 (es)
NZ (1) NZ326754A (es)
PL (1) PL185714B1 (es)
RU (1) RU2201227C2 (es)
SK (1) SK283222B6 (es)
TW (1) TW457084B (es)
UA (1) UA51681C2 (es)
WO (1) WO1997015300A2 (es)
ZA (1) ZA968991B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
US7205307B2 (en) * 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
BR0317748A (pt) * 2002-12-27 2005-11-22 Lundbeck & Co As H Composto, composição farmacêutica, e,uso de um composto
PT1578740E (pt) * 2002-12-27 2007-05-31 Lundbeck & Co As H Derivados de 1, 2, 4-triaminobenzeno úteis para tratamento de distúrbios do sistema nervoso central
WO2004096767A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
WO2006092143A1 (en) 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8293911B2 (en) * 2006-08-23 2012-10-23 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
WO2008066900A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
CA2731008A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
WO2013011518A1 (en) 2011-07-21 2013-01-24 Arch Pharmalabs Limited Process for the preparation of retigabine of the formula i and pharmaceutically acceptable salts thereof
CN103073455B (zh) 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
US9517223B2 (en) 2012-08-07 2016-12-13 The General Hospital Corporation Methods to treat neurodegenerative diseases
CN105017085B (zh) 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3155812A1 (en) 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methods of treating depressive disorders
CN116847843A (zh) 2021-02-09 2023-10-03 泽农医药公司 用于治疗快感缺乏的电压门控的钾通道开放剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2817334B2 (ja) * 1990-03-29 1998-10-30 株式会社ツムラ 神経細胞保護剤
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
TW280819B (es) * 1993-11-17 1996-07-11 Sumitomo Pharma
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen

Also Published As

Publication number Publication date
ID16489A (id) 1997-10-02
SK52098A3 (en) 1998-09-09
SK283222B6 (sk) 2003-03-04
PL185714B1 (pl) 2003-07-31
PL325956A1 (en) 1998-08-17
BR9610899A (pt) 1999-07-13
ATE178487T1 (de) 1999-04-15
NZ326754A (en) 2000-03-27
DK0857065T3 (da) 1999-10-18
HU228014B1 (en) 2012-08-28
NO981503L (no) 1998-04-02
KR100423823B1 (ko) 2004-08-25
AU1540097A (en) 1997-05-15
US5852053A (en) 1998-12-22
GR3030336T3 (en) 1999-09-30
JP4567101B2 (ja) 2010-10-20
IL123523A (en) 2001-12-23
HUP9900508A2 (hu) 1999-06-28
HUP9900508A3 (en) 1999-11-29
AR004108A1 (es) 1998-09-30
EP0857065B1 (de) 1999-04-07
CZ291456B6 (cs) 2003-03-12
DE59601624D1 (de) 1999-05-12
EP0857065A2 (de) 1998-08-12
RU2201227C2 (ru) 2003-03-27
TW457084B (en) 2001-10-01
US5849789A (en) 1998-12-15
KR19990067021A (ko) 1999-08-16
IL123523A0 (en) 1998-10-30
UA51681C2 (uk) 2002-12-16
CZ122598A3 (cs) 1998-09-16
ZA968991B (en) 1997-06-10
DE19539861A1 (de) 1997-04-30
WO1997015300A2 (de) 1997-05-01
AU706735B2 (en) 1999-06-24
CA2188841A1 (en) 1997-04-27
CA2188841C (en) 2006-05-23
JP2009007366A (ja) 2009-01-15
MX9803172A (es) 1998-09-30
WO1997015300A3 (de) 1997-07-03
JPH11515007A (ja) 1999-12-21
NO981503D0 (no) 1998-04-02
NO316493B1 (no) 2004-02-02

Similar Documents

Publication Publication Date Title
ES2131973T3 (es) Empleo de 2-amino-4-(4-fluorobencilamino)-1-etoxicarbonilaminobencenos para la profilaxis y el tratamiento de las secuelas de la disminucion aguda y cronica del riego sanguineo cerebral, asi como de afecciones neurodegenerativas.
ES2186670T3 (es) Derivados de prostaglandina para el tratamiento del glaucoma o la hipertension ocular.
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
DOP2002000429A (es) Imidazotriazinas
ES2148229T3 (es) Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
BG107537A (bg) Инхибиране на човешка tnf алфа активност
DK1676579T3 (da) Anvendelse af sub-antimikrobielle tetracykliner til behandling af okulær rosacea
MX9305269A (es) Utilizacion del receptor de il-4 para la terapia,la profilaxis y el diagnostico de enfermedades alergicas, viricas, parasitarias y bacterianas asi como de infecciones por hongos.
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
DE3774918D1 (de) Cancerostatisches mittel.
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
ES2157252T3 (es) Aplicacion del riluzol en el tratamiento del neuro-sida.
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
ES2136091T3 (es) Inhibidores de catepsina g y elastasa para prevenir la degradacion del tejido conectivo.
ATE78031T1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
ES2159889T3 (es) 15-fluoro prostaglandinas utilizadas como hipotensores oculares.
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
IT1318667B1 (it) Medicamento antinfiammatorio.
ES2177849T3 (es) Preparado farmaceutico, que contiene 2-fenil-1,2-benzoisoselenazol-3(2h)-ona, para el tratamiento de la enfermedad de alzheimer.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
ES2141330T3 (es) Monohidrato de (e)-2'-desoxi-2'-(fluorometileno)citidina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 857065

Country of ref document: ES